- Home
- STR vs WVE Comparison
STR vs WVE Comparison
Compare STR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- WVE
- Stock Information
- Founded
- STR 2016
- WVE 2012
- Country
- STR United States
- WVE Singapore
- Employees
- STR N/A
- WVE N/A
- Industry
- STR Oil & Gas Production
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- STR Energy
- WVE Health Care
- Exchange
- STR Nasdaq
- WVE Nasdaq
- Market Cap
- STR 1.6B
- WVE 1.7B
- IPO Year
- STR N/A
- WVE 2015
- Fundamental
- Price
- STR $20.22
- WVE $8.62
- Analyst Decision
- STR Buy
- WVE Strong Buy
- Analyst Count
- STR 5
- WVE 11
- Target Price
- STR $28.25
- WVE $22.00
- AVG Volume (30 Days)
- STR 810.3K
- WVE 1.3M
- Earning Date
- STR 05-07-2025
- WVE 03-04-2025
- Dividend Yield
- STR 6.93%
- WVE N/A
- EPS Growth
- STR N/A
- WVE N/A
- EPS
- STR 0.49
- WVE N/A
- Revenue
- STR $624,414,000.00
- WVE $108,302,000.00
- Revenue This Year
- STR N/A
- WVE N/A
- Revenue Next Year
- STR $3.12
- WVE $33.28
- P/E Ratio
- STR $41.22
- WVE N/A
- Revenue Growth
- STR 5.23
- WVE N/A
- 52 Week Low
- STR $18.40
- WVE $4.25
- 52 Week High
- STR $25.95
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- STR 52.65
- WVE 36.64
- Support Level
- STR $20.12
- WVE $9.43
- Resistance Level
- STR $21.09
- WVE $10.91
- Average True Range (ATR)
- STR 0.51
- WVE 0.70
- MACD
- STR 0.09
- WVE -0.07
- Stochastic Oscillator
- STR 63.14
- WVE 5.45
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.